FDA Clears Emerging AI-Powered Software for Brain MRI
Leveraging AI technology, the AiMIFY software reportedly facilitates double the contrast enhancement in comparison to gadolinium-based contrast agents (GBCAs) for brain MRI.
Offering enhanced imaging capability for detection of lesions on brain magnetic resonance imaging (MRI), the artificial intelligence (AI)-enabled software AiMIFY has been granted clearance from the Food and Drug Administration (FDA) for a class II software as a medical device (SaMD).
Co-developed by Bracco Diagnostics and Subtle Medical, AiMIFY enhances contrast on brain MRI to a level that is double the contrast generated with labeled dosing of gadolinium-based contrast agents (GBCAs). The increased imaging clarity bolsters the detection of small lesions on brain MRI, according to the companies.
The recently FDA-cleared AI software AiMIFY reportedly enhances contrast on brain MRI to a level that is double the contrast generated with labeled dosing of gadolinium-based contrast agents (GBCAs). (Image courtesy of Adobe Stock.)
The companies emphasized research validation of aiMIFY use with a variety of vendor scanners and MRI sequences as well as datasets including diverse patient demographics and pathologies.
"By integrating Bracco's expertise in contrast imaging with Subtle Medical's cutting-edge deep-learning technology, we are poised to redefine diagnostic precision and efficiency, setting new standards in the field for the ultimate benefit of the patients,” noted Fulvio Renoldi Bracco, the vice chairman and CEO of Bracco Imaging.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
